Načítá se...
Prevention of β Thalassemia in Northern Israel - a Cost-Benefit Analysis
BACKGROUND: β Thalassemia major is characterized by hemolytic anemia, ineffective erythropoiesis and hemosiderosis. About 4% of the world population carries a Thalassemia gene. Management includes blood transfusions and iron chelation. However, this treatment is costly, and population screening may...
Uloženo v:
| Hlavní autoři: | , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Università Cattolica del Sacro Cuore
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3965716/ https://ncbi.nlm.nih.gov/pubmed/24678389 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4084/MJHID.2014.012 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|